Governance Amgen Inc.

AMGN

US0311621009

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 21:00:00 12/02/2026 GMT			5-day change	1st Jan Change
366.20 ^USD	-0.10%		-0.44%	+11.88%

02-12	Amgen Inc. Presents at Piper Sandler Virtual Novel Targets in Immunology Symposium, Feb-12-2026 05:00 PM
02-12	European Commission approves Amgen's Uplizna® for generalized myasthenia gravis	RE

Executive Committee: Amgen Inc.

Manager

Positions heldSince

Robert Bradway

63 year

Chief Executive Officer	30/04/2012
President	30/04/2010

Scott Skellenger

Chief Tech/Sci/R&D Officer

30/09/2022

Howard Y. Chang

Chief Tech/Sci/R&D Officer

15/12/2024

Paul Burton

57 year

Chief Tech/Sci/R&D Officer

31/05/2023

James Bradner

53 year

Chief Tech/Sci/R&D Officer

17/12/2023

Matthew Busch

52 year

Comptroller/Controller/Auditor

13/08/2023

Derek Miller

53 year

Human Resources Officer

31/08/2004

Mark J. Taisey

General Counsel

31/12/2013

Nancy Grygiel

58 year

Compliance Officer

31/12/2015

Peter Griffith

67 year

Director of Finance/CFO

31/12/2019

Esteban Santos

59 year

Chief Operating Officer

24/07/2016

Jonathan Graham

65 year

General Counsel	12/07/2015
Corporate Secretary	12/07/2015

David Reese

63 year

Chief Tech/Sci/R&D Officer

25/07/2018

Composition of the Board of Directors: Amgen Inc.

Director

CommitteesSince

Robert Bradway

63 year

Executive Committee Chair	31/12/2012
Compensation Committee	13/10/2016
Governance Committee Chair

Robert Eckert

71 year

Compensation Committee	25/03/2021
HR Committee	25/03/2021
Governance Committee Chair	25/03/2021
Nominating Committee Chair	25/03/2021
Executive Committee	31/12/2011
Governance Committee	19/03/2020
Nominating Committee	19/03/2020
Compensation Committee Chair

Greg Garland

68 year

Executive Committee
Compensation Committee	15/10/2013
Governance Committee Chair
Nominating Committee Chair
Audit Committee	02/11/2025
Finance Committee	02/11/2025

Charles Holley

69 year

Executive Committee	02/02/2017
Governance Committee
Nominating Committee	02/02/2017
Audit Committee Chair	31/03/2020
Audit Committee	03/10/2019
Finance Committee	03/10/2019

Wanda Austin

71 year

Compensation Committee	23/10/2017
Governance Committee Chair	30/11/2016
Nominating Committee Chair	30/11/2016
Audit Committee
Finance Committee

Amy Miles

59 year

Governance Committee	14/01/2025
Audit Committee Chair
Finance Committee Chair	31/03/2020
Audit Committee	14/01/2025
Nominating Committee	22/07/2020

Ellen Kullman

70 year

Governance Committee Chair	07/05/2023
Nominating Committee Chair	07/05/2023
Governance Committee	20/12/2016
Nominating Committee	20/12/2016
Compensation Committee	20/12/2016

Omar Ishrak

71 year

Audit Committee	31/07/2023
Compensation Committee	29/07/2021
Governance Committee	31/07/2023
Nominating Committee	31/07/2023

Mary Klotman

72 year

Governance Committee	30/05/2024
Nominating Committee	10/11/2022
Compensation Committee	10/11/2022

Tyler Jacks

65 year

Finance Committee	23/02/2015
Compensation Committee

Michael Drake

75 year

Governance Committee	02/08/2022
Nominating Committee	02/08/2022

Brian Druker

70 year

Compensation Committee

22/05/2018

Latest Appointments: Amgen Inc.

02-03	Pyxis Oncology, Inc. Announces Chief Executive Officer Changes, Effective February 3, 2026	CI
01-28	Vera Therapeutics Announces Appointment of Matt Skelton as Chief Commercial Officer, Effective January 28, 2026	CI
01-26	Janux Therapeutics, Inc. Announces Chief Medical Officer Changes	CI
01-22	MBX Biosciences, Inc. Announces Board and Committee Changes	CI
01-13	Aligos Therapeutics, Inc. Appoints James Hassard as Executive Vice President and Chief Commercial Officer, Effective January 13, 2026	CI
01-12	BioMarin Pharmaceutical Names Arpit Dave Chief Digital and Information Officer	MT
01-12	BioMarin Pharmaceutical Inc. Appoints Arpit Davé as Executive Vice President and Chief Digital and Information Officer	CI

More news

Former Officers and Directors: Amgen Inc.

Insider

Positions held

SinceUntil

Frank Herringer

Director/Board Member	30/04/2004	21/05/2019
Independent Dir/Board Member	21/04/2011	21/05/2019

David Baltimore

Director/Board Member	31/12/1996	21/05/2018
Independent Dir/Board Member	21/04/2011	21/05/2018

Frank J. Biondi

Director/Board Member	31/12/2001	18/05/2017
Independent Dir/Board Member	21/04/2011	18/05/2017

Judith C. Pelham

Director/Board Member	30/04/1995	18/05/2017
Independent Dir/Board Member	21/04/2011	18/05/2017

Rolf K. Hoffmann

Corporate Officer/Principal

31/10/2004

30/06/2016

Vance D. Coffman

Director/Board Member	01/10/2007	31/12/2015
Independent Dir/Board Member	21/04/2011	31/12/2015

Willard Dere

Chief Tech/Sci/R&D Officer	31/05/2007	30/09/2014
Corporate Officer/Principal	31/05/2007	31/05/2007

Joseph P. Miletich

Chief Tech/Sci/R&D Officer

31/03/2002

30/06/2014

Gilbert Omenn

Director/Board Member	31/12/1986	14/05/2014
Independent Dir/Board Member	21/04/2011	14/05/2014

Leonard Schaeffer

Director/Board Member	29/02/2004	07/07/2013
Independent Dir/Board Member	21/04/2011	07/07/2013

J. Reason

Director/Board Member	31/12/2000	21/05/2013
Independent Dir/Board Member	21/04/2011	21/05/2013

Fabrizio Bonanni

Chief Operating Officer

31/03/1999

31/12/2012

David Beier

Public Communications Contact	18/04/2011	07/10/2012
General Counsel	30/11/2003	07/10/2012
Corporate Officer/Principal	07/10/2012	31/12/2012

Kevin Sharer

Chief Executive Officer	31/12/1999	30/04/2012
Chairman	01/10/1992	30/12/2012
President	01/10/1992	31/12/1999

Roger Perlmutter

Chief Tech/Sci/R&D Officer

31/12/2000

11/02/2012

Roy Baynes

Corporate Officer/Principal

31/07/2002

31/12/2011

Frederick Gluck

Director/Board Member	31/01/1998	30/09/2011
Independent Dir/Board Member	21/04/2011	30/09/2011

Lisa Guttman

Corporate Officer/Principal

31/12/1999

30/09/2007

Richard Nanula

Director of Finance/CFO

31/07/2001

09/04/2007

Donald B. Rice

Director/Board Member

30/09/2000

16/01/2007

Lisa A. Evrén

Treasurer

31/12/2001

31/12/2006

Hassan A. Dayem

Chief Tech/Sci/R&D Officer

30/04/2002

19/09/2006

Timothy Martin

Comptroller/Controller/Auditor	31/07/2003	30/04/2006
Director of Finance/CFO	31/07/2003	30/04/2006

David Parkinson

Corporate Officer/Principal

30/04/2003

28/02/2006

Keith L. Klein

General Counsel

31/12/1990

31/12/2005

Edward V. Fritzky

Director/Board Member

30/06/2002

30/04/2005

Charles R. Bradley

Corporate Officer/Principal

31/12/1999

31/12/2004

Michael Narachi

Corporate Officer/Principal

30/06/1984

31/12/2002

Thomas James Flanagan

Chief Tech/Sci/R&D Officer

31/05/2004

Steve Lazarus

Director/Board Member

30/04/1987

12/05/2004

Patricia Cary Sueltz

Director/Board Member	07/01/2002	30/04/2004
Independent Dir/Board Member	07/01/2002	30/04/2004

David J. Scott

General Counsel	29/02/2004	-
Corporate Secretary	29/02/2004	-

Joseph J. Tsiakals

Corporate Officer/Principal

31/12/1999

31/12/2003

Bradley J. Maroni

Corporate Officer/Principal

31/12/1997

31/12/2003

Martha E. Vincent

Chief Tech/Sci/R&D Officer

31/12/1994

31/12/2003

Kevin B. Young

Corporate Officer/Principal

31/12/2000

31/12/2003

Wen-Tse Tseng

Corporate Officer/Principal

09/09/1998

09/09/2003

Diane M. Palumbo

Human Resources Officer

31/05/1991

30/06/2003

Carl LeBel

Corporate Officer/Principal

31/12/1992

David Hallal

Sales & Marketing

31/12/1991

31/07/2002

Nicholas Lydon

Corporate Officer/Principal

30/11/2000

01/01/2002

Robin D. Campbell

Corporate Officer/Principal

31/12/1988

31/12/2001

Brian M. McNamee

Human Resources Officer	31/05/2001	06/11/2013
Corporate Officer/Principal	06/11/2013	-

Matthew Moyle

Corporate Officer/Principal

31/12/1994

31/12/2000

Gordon Binder

Chief Executive Officer

31/12/1981

31/12/1999

Henry Wu

Corporate Officer/Principal

31/12/1998

Gisela Schwab

Chief Tech/Sci/R&D Officer

31/12/1991

Denny Lanfear

Corporate Officer/Principal

31/12/1985

31/12/1998

Jerry D. Choate

Director/Board Member	31/07/1998	-
Independent Dir/Board Member	21/04/2011	-

Julia Eastland

Comptroller/Controller/Auditor

29/02/1996

31/03/1998

Danute M. Bankaitis-Davis

Chief Tech/Sci/R&D Officer

31/12/1991

31/12/1997

Rosemary Mazanet

Chief Tech/Sci/R&D Officer

31/12/1992

31/12/1997

Kathleen M. Wiltsey

Sales & Marketing

31/12/1983

31/12/1997

Margaret E. Valeur-Jensen

Corporate Officer/Principal

31/12/1990

31/12/1997

Gregory Stea

Sales & Marketing

30/04/1988

31/12/1996

Peter García

Corporate Officer/Principal

31/12/1989

Richard Yeh

Corporate Officer/Principal

01/10/1995

Mark Moon

Corporate Officer/Principal

31/12/1988

01/01/1995

Lowell Sears

Director of Finance/CFO

31/12/1985

31/12/1993

Alan B. Forsythe

Corporate Officer/Principal

31/12/1990

G. Kirk Raab

Director/Board Member

31/12/1980

31/12/1984

Bertrand C. Liang

Corporate Officer/Principal

Joshua Disbrow

Corporate Officer/Principal

Alexander Lopez

Corporate Officer/Principal

Elaine Richardson

Corporate Officer/Principal

Howard J. Lewin

Corporate Officer/Principal

Edward H. Shin

Corporate Officer/Principal

David Polk

Public Communications Contact

Alec Green

Corporate Officer/Principal

Jeffrey D. Webster

Corporate Officer/Principal

M. Patricia Beckmann

Corporate Officer/Principal

Nancy Stuart

Corporate Officer/Principal

Ralph Niven

Corporate Officer/Principal

Kathleen Stafford

Treasurer

Steve Bandler

Corporate Officer/Principal

Sanjay Kanungo

Corporate Officer/Principal

Steven R. Wiley

Corporate Officer/Principal

James H. Chamberlain

Corporate Officer/Principal

John Shutter

Public Communications Contact

Luc Marengère

Corporate Officer/Principal

Ernest Allen

Corporate Officer/Principal

Age distribution of managers

Parity Men Women

Male	25
Female	6

Of which Executive Committee

Male	12
Female	1

Of which Directors

Male	10
Female	2

Revisions

Révisions CA 1 an

Révisions CA 4 mois

Révisions CA 1 mois

Révisions BNA 1 an

Révisions BNA 4 mois

ESG MSCI

Environnement

Social

Gouvernance

Polémique

Controverses Ethiques

Controverses sur les droits de l'Homme

Controverses Subventions fiscales

Yes

Conforme à la finance Islamique

Amgen Inc. is one of the world's leading biotechnology groups. Net sales break down by source of revenue as follows: - drug sales (95.8%): drugs for treating cancer, metabolic disorders, bone diseases, renal failure, hemophilia, etc.; - other 4.2%): primarily royalties. The United States account for 71.4% of net sales.

Employees

28,000

Sector

Pharmaceuticals

Calendar

12/02/2026 -

More about the company